Pharmaceuticals, Biotechnology & Life Sciences

OrbiMed’s recent sell‑offs of 93k Adicet Bio shares signal a routine liquidity move, not a confidence drop—investors should watch clinical milestones and market sentiment for next‑step insights.

Ovid Therapeutics’ latest RSU grant for board member Stelios Papadopoulos signals insider confidence, boosting investor optimism ahead of the KCC2 data release.

Insider buying surges at Stablecoin Development Corp.—CFO’s 300k RSU exercise fuels confidence, hints at long‑term growth, and could stabilize the stock.

Harmony Biosciences insider trades reveal balanced strategy: CEO & COO buying, selling, and liquidating RSUs, indicating confidence and long‑term growth potential.

Levine Zurit’s disciplined 10b5‑1 trades show Compugen’s exec buying low and selling high, boosting investor confidence in the company’s rising biotech outlook.

Insider trading at Zai Lab shows CEO Du Ying’s liquidity‑managing buy‑sell‑buy cycle, with short‑term gains yet strong long‑term confidence in the biotech’s pipeline.

CEO Michael Egholm’s zero‑cost RSU purchases show strong insider confidence in Standard BioTools, signaling a long‑term growth bet and a potential catalyst for investor interest.

Insightful insider sales at Zai Lab reveal a tax‑covering move, not a distress signal, amid a 38% stock surge and biotech pipeline excitement.

Corcept insider buys reveal executive confidence amid legal risk, showing disciplined buying and long‑term optimism for investors.

Insider buying and selling at PTC shows exec confidence: Boulding’s $39.42 purchase amid $70 sales signals long‑term upside for the biotech.